Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the transaction, the chief operating officer now directly owns 69,266 shares in the company, valued at approximately $6,581,655.32. This represents a 3.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Christina Rossi also recently made the following trade(s):

• On Tuesday, January 21st, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $110.14, for a total transaction of $250,458.36.

Blueprint Medicines Stock Down 1.1 %

NASDAQ BPMC opened at $88.72 on Friday. The stock’s 50 day simple moving average is $98.13 and its 200 day simple moving average is $93.93. Blueprint Medicines Co. has a one year low of $80.68 and a one year high of $121.90. The firm has a market cap of $5.67 billion, a PE ratio of -82.15 and a beta of 0.58. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, sell-side analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $128.00 price target on shares of Blueprint Medicines in a report on Friday, February 28th. Jefferies Financial Group began coverage on shares of Blueprint Medicines in a research report on Monday, March 17th. They set a “buy” rating and a $135.00 price objective for the company. Stephens reissued an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. Finally, Piper Sandler lifted their price objective on Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $124.95.

Institutional Investors Weigh In On Blueprint Medicines

A number of hedge funds have recently added to or reduced their stakes in BPMC. Quarry LP acquired a new position in shares of Blueprint Medicines during the third quarter worth approximately $32,000. R Squared Ltd bought a new position in Blueprint Medicines in the 4th quarter worth approximately $51,000. Headlands Technologies LLC bought a new position in Blueprint Medicines in the 4th quarter worth approximately $65,000. Thematics Asset Management acquired a new position in Blueprint Medicines during the 4th quarter worth $72,000. Finally, Covestor Ltd boosted its position in Blueprint Medicines by 62.7% in the 4th quarter. Covestor Ltd now owns 973 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 375 shares during the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.